Nuvaxovid
COVID-19 Vaccine (recombinant, adjuvanted)
Overview
Nuvaxovid is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 12 years and older.
The originally authorised Nuvaxovid contains a version of a protein found on the surface of SARS CoV 2 (the virus that causes COVID-19), which has been produced in the laboratory.
Nuvaxovid is also available as an adapted vaccine, Nuvaxovid XBB.1.5, which contains a version of the protein from the Omicron XBB.1.5 subvariant of SARS-CoV-2.
-
List item
Nuvaxovid : EPAR - Medicine overview (PDF/146.35 KB) (updated)
First published: 20/12/2021
Last updated: 08/11/2023
EMA/488650/2023 -
List item
Nuvaxovid : EPAR - Risk-management-plan (PDF/1.66 MB)
First published: 20/12/2021
Last updated: 10/01/2023
Authorisation details
Product details | |
---|---|
Name |
Nuvaxovid
|
Agency product number |
EMEA/H/C/005808
|
Active substance |
|
International non-proprietary name (INN) or common name |
COVID-19 Vaccine (recombinant, adjuvanted)
|
Therapeutic area (MeSH) |
COVID-19 virus infection
|
Anatomical therapeutic chemical (ATC) code |
J07BN04
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Publication details | |
---|---|
Marketing-authorisation holder |
Novavax CZ, a.s.
|
Revision |
11
|
Date of issue of marketing authorisation valid throughout the European Union |
20/12/2021
|
Contact address |
Bohumil 138 |
Product information
31/10/2023 Nuvaxovid - EMEA/H/C/005808 - II/0058/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Covid-19 vaccines
Therapeutic indication
Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
Nuvaxovid XBB.1.5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
Assessment history
Safety updates
-
List item
NUVAXOVID: Periodic safety update report assessment 20 June 2022 to 19 December 2022 (PDF/2.87 MB)
First published: 24/10/2023 -
List item
COVID-19 vaccines - Safety update: 8 December 2022 (PDF/720.9 KB) (updated)
First published: 08/12/2022
Last updated: 01/12/2023 -
List item
COVID-19 vaccines - Safety update: 10 November 2022 (PDF/726.69 KB) (updated)
Adopted
First published: 10/11/2022
Last updated: 01/12/2023 -
List item
COVID-19 vaccines - Safety update: 6 October 2022 (PDF/716.78 KB) (updated)
Adopted
First published: 06/10/2022
Last updated: 01/12/2023 -
List item
COVID-19 vaccines - Safety update: 8 September 2022 (PDF/729.47 KB) (updated)
Adopted
First published: 08/09/2022
Last updated: 01/12/2023 -
List item
COVID-19 vaccines - Safety update: 14 July 2022 (PDF/731.54 KB) (updated)
Adopted
First published: 14/07/2022
Last updated: 01/12/2023
Rev. 1 -
List item
COVID-19 vaccines - Safety update: 17 June 2022 (PDF/235.43 KB)
Adopted
First published: 17/06/2022 -
List item
COVID-19 vaccines - Safety update: 12 May 2022 (PDF/203.03 KB)
Adopted
First published: 12/05/2022 -
List item
COVID-19 vaccines - Safety update: 13 April 2022 (PDF/214.65 KB)
Adopted
First published: 13/04/2022 -
List item
COVID-19 vaccines - Safety update: 17 March 2022 (PDF/221.74 KB)
Adopted
First published: 17/03/2022 -
List item
COVID-19 vaccines - Safety update: 17 February 2022 (PDF/212.51 KB)
Adopted
First published: 17/02/2022 -
List item
COVID-19 vaccines - Safety update: 20 January 2022 (PDF/234.12 KB)
Adopted
First published: 20/01/2022